Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: a third look.
Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21%) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D012008:Recurrence; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000556:secondary
D004317:Doxorubicin; D008727:Methotrexate